Cartesian Therapeutics announces participation in September investor conferences, discussing its autoimmune disease therapies and clinical developments.
Quiver AI Summary
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a biotechnology company focused on cell therapies for autoimmune diseases, announced its participation in several investor conferences in September 2025. The events include a fireside chat at the Cantor Global Healthcare Conference on September 4, a chat at Morgan Stanley's Healthcare Conference on September 9, and a presentation at the H.C. Wainwright Global Investment Conference on September 10. Live webcasts of these sessions will be available on the company's website, along with archived versions for a limited time. The company is advancing its lead product, Descartes-08, a CAR-T therapy in Phase 3 for generalized myasthenia gravis and Phase 2 for systemic lupus erythematosus, with plans for further trials in other autoimmune diseases.
Potential Positives
- Participation in multiple high-profile investor conferences indicates strong visibility and engagement with the investment community.
- The presentation of innovative cell therapy solutions, including Descartes-08 and Descartes-15, highlights the company's commitment to advancing treatments for autoimmune diseases, potentially attracting interest from investors and partners.
- Live webcasts and archived replays of presentations provide transparency and accessibility for investors, enhancing communication and trust with stakeholders.
Potential Negatives
- The press release does not provide any new information about the company's clinical trial progress or results, which could lead to investor concern about a lack of transparency or updates on significant developments.
- There is no mention of any partnerships, collaborations, or funding, which may raise questions about the company's financial stability and resources for ongoing development.
- The release highlights participation in investor conferences but lacks information about any anticipated outcomes or goals from these events, potentially reflecting uncertainty in the company's strategic direction.
FAQ
What investor conferences will Cartesian Therapeutics participate in September 2025?
Cartesian Therapeutics will participate in the Cantor Global Healthcare Conference, Morgan Stanley's Healthcare Conference, and H.C. Wainwright Global Investment Conference.
When are the presentations scheduled for Cartesian Therapeutics?
The presentations are scheduled for September 4, September 9, and September 10, 2025, at various times.
Where can I watch the live webcasts of the events?
The live webcasts will be available in the Events section of Cartesian Therapeutics' website.
What is Cartesian Therapeutics known for?
Cartesian Therapeutics is pioneering cell therapy specifically for autoimmune diseases.
What clinical developments does Cartesian Therapeutics have?
The company has clinical assets including Descartes-08 for myasthenia gravis and Descartes-15 for multiple myeloma.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RNAC Insider Trading Activity
$RNAC insiders have traded $RNAC stock on the open market 13 times in the past 6 months. Of those trades, 13 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RNAC stock by insiders over the last 6 months:
- TIMOTHY A SPRINGER has made 13 purchases buying 238,938 shares for an estimated $2,893,671 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RNAC Hedge Fund Activity
We have seen 28 institutional investors add shares of $RNAC stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 188,957 shares (-96.9%) from their portfolio in Q2 2025, for an estimated $1,963,263
- MPM BIOIMPACT LLC removed 104,772 shares (-13.2%) from their portfolio in Q2 2025, for an estimated $1,088,581
- 683 CAPITAL MANAGEMENT, LLC added 69,000 shares (+46.0%) to their portfolio in Q2 2025, for an estimated $716,910
- MARSHALL WACE, LLP added 44,025 shares (+114.0%) to their portfolio in Q2 2025, for an estimated $457,419
- JACOBS LEVY EQUITY MANAGEMENT, INC added 41,317 shares (+inf%) to their portfolio in Q2 2025, for an estimated $429,283
- CITADEL ADVISORS LLC removed 26,423 shares (-17.9%) from their portfolio in Q2 2025, for an estimated $274,534
- GSA CAPITAL PARTNERS LLP added 24,811 shares (+147.8%) to their portfolio in Q2 2025, for an estimated $257,786
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RNAC Analyst Ratings
Wall Street analysts have issued reports on $RNAC in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wedbush issued a "Outperform" rating on 07/09/2025
- Needham issued a "Buy" rating on 05/08/2025
- HC Wainwright & Co. issued a "Buy" rating on 04/09/2025
To track analyst ratings and price targets for $RNAC, check out Quiver Quantitative's $RNAC forecast page.
$RNAC Price Targets
Multiple analysts have issued price targets for $RNAC recently. We have seen 3 analysts offer price targets for $RNAC in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Martin Fan from Wedbush set a target price of $38.0 on 07/09/2025
- Gil Blum from Needham set a target price of $40.0 on 05/08/2025
- Mitchell Kapoor from HC Wainwright & Co. set a target price of $40.0 on 04/09/2025
Full Release
FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:
- A fireside chat at the Cantor Global Healthcare Conference 2025 at 11:30 a.m. ET on Thursday, September 4, 2025
- A fireside chat at Morgan Stanley’s 23 rd Annual Healthcare Conference at 4:05 p.m. ET on Tuesday, September 9, 2025
-
A presentation at the H.C. Wainwright 27
th
Annual Global Investment Conference at 8:30 a.m. ET on Wednesday, September 10, 2025
Live webcasts of the fireside chats and presentation are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com , where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X , formerly known as Twitter.
Investor Contact
Megan LeDuc
Associate Director, Investor Relations
[email protected]
Media Contact
David Rosen
Argot Partners
[email protected]
